期刊文献+

2021年河南省新型冠状病毒Delta变异株肺炎流行病学及分子特征研究

Epidemiological and molecular characteristics of SARS-CoV-2 Delta variant-caused pneumonia in Henan Province in 2021
原文传递
导出
摘要 目的:分析总结2021年河南省新型冠状病毒(severe acute respiratory syndrome coronavirus,SARS-CoV-2)Delta变异株肺炎流行病学及分子特征,为疫情防控提供依据。方法:依据中国疾病预防控制中心(Chinese Centre for Disease Control and Prevention,CDC)反馈测序结果,挑选2021年河南入境和本土病例为SARS-CoV-2 Delta变异株肺炎患者111例,从大疫情网上获得患者基本信息,对年龄、性别、是否接种疫苗、接种剂次、RT-qPCR检测ORF1 ab基因和N基因Ct值在不同性别及不同症状病例间有无差异、患者临床分型等进行统计学分析,对测序结果核苷酸及刺突蛋白(spike protein,S)突变位点进行分析,总结规律。结果:111个病例在不同年龄组间的性别分布差异无统计学意义(χ^(2)=2.217,P=0.529)。不同疫苗接种史人群中的病例类型差异无统计学意义(χ^(2)=12.074,P=0.209)。SARS-CoV-2核酸阳性标本中,大部分标本Ct值分布在较低区间,病毒载量较高。ORF1 ab基因Ct值在不同性别间的差异无统计学意义(χ^(2)=1.646,P=0.439),在无症状感染者、轻型、普通、重型之间差异具有统计学意义(χ^(2)=13.257,P=0.039)。N基因Ct值在不同性别及不同症状病例间差异均无统计学意义(P均>0.05)。本研究的111例患者主要通过密接筛查和全员核酸筛查发现,两者共占总体的62.2%(69例)。测序长度覆盖度基本都大于99%(占90.1%,100/111),核苷酸突变位点总数多为46~50个(86.4%,89/103),S蛋白突变位点总数多为12个(82.5%,85/103)。103株Delta变异株均含有T19R、R158G、L452R、T478K、D614G、P681R、D950N、E156del、F157del这9个突变位点,突变率为100%。结论:2021年河南省SARS-CoV-2 Delta变异株对人群普遍易感;病毒载量高,ORF1 ab基因载量增高会加重临床症状。 Objective To analyze and summarize the epidemiological and molecular characteristics of SARS-CoV-2 Delta variant,a variant of concern(VOC),in Henan Province in 2021 in order to provide a basis for epidemic prevention and control.Methods According to the feedback of sequencing results from Chinese Center for Disease Control and Prevention,111 patients infected with SARS-CoV-2 Delta VOC were selected from the Henan imported and local cases in 2021.Basic patient information was obtained from the pandemic website.The differences in age,gender,vaccination history,the number of vaccine doses and different clinical types were analyzed.Moreover,the differences in RT-qPCR results of ORF1ab gene and N gene Ct values between cases of different genders and symptoms were analyzed statistically.Sequencing results of the nucleotide and S protein mutation sites were analyzed.Results There was no significant difference in the gender distribution of 111 cases between different age groups(χ^(2)=2.217,P=0.529).There was also no significant difference in clinical types between patients with different vaccination history(χ^(2)=12.074,P=0.209).The Ct values of most SARS-CoV-2 nucleic acid-positive specimens were distributed in the lower range and the viral loads were higher.The difference in the Ct value of ORF1ab gene between different gender groups was not statistically significant(χ^(2)=1.646,P=0.439),but were significantly different among asymptomatic,mild,normal,and severe cases(χ^(2)=13.257,P=0.039).There was no significant difference in N gene Ct value among cases of different genders or different symptoms(all P>0.05).The 111 patients in this study were mainly found through close-contact screening and full-staff nucleic acid screening and accounted for 62.2%(69 cases)of the total.The sequencing length coverage was basically greater than 99%(accounting for 90.1%,100/111);the total number of nucleotide mutation sites was mostly in the range of 46-50(86.4%,89/103);the total number of S protein mutation sites was mostly 12(82.5%,85/103).The 103 Delta mutants all contained nine mutation sites,which were T19R,R158G,L452R,T478K,D614G,P681R,D950N,E156del and F157del,with a mutation rate of 100%.Conclusions People were highly susceptible to the SARS-CoV-2 Delta in Henan Province in 2021.High viral load and increase in the ORF1ab gene load would aggravate the clinical symptoms.
作者 李金月 许玉玲 王海霞 夏向群 宋云 黄学勇 Li Jinyue;Xu Yuling;Wang Haixia;Xia Xiangqun;Song Yun;Huang Xueyong(Henan Key Laboratory of Infectious Disease Microbiology,Infectious Disease Control and Prevention Institute,Henan Provincial Center for Disease Control and Prevention,Zhengzhou 450016,China)
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2022年第1期11-15,共5页 Chinese Journal of Microbiology and Immunology
基金 河南省省部共建重大专项(SBGJ202001003) 新型冠状病毒防控应急攻关首批项目(201100310800) 河南省中青年卫生健康科技创新领军人才培养项目(YXKC2020006)。
关键词 新型冠状病毒 新型冠状病毒Delta变异株 S蛋白 ORF1 ab基因 N基因 SARS-CoV-2 Delta VOC S protein ORF1ab gene N gene
  • 相关文献

参考文献5

二级参考文献11

  • 1吴玉章,朱锡华.一种病毒蛋白B细胞表位预测方法的建立[J].科学通报,1994,39(24):2275-2279. 被引量:81
  • 2魏光河.4种方法去除血浆纤维蛋白原的效果比较[J].中国兽医杂志,2015,51(3):36-39. 被引量:1
  • 3王新珍,王凤花,孙瑞波,刘彬彬.高通量测序技术在微生物分子生态学研究中的应用[J].中国生态农业学报,2018,26(10):1593-1600. 被引量:24
  • 4杨振宇,张临政,刘俊香.冠状病毒治疗性抗体专利分析[J].中国发明与专利,2020,17(3):23-29. 被引量:3
  • 5M.Ablikim,M.N.Achasov,P.Adlarson,S.Ahmed,M.Albrecht,M.Alekseev,A.Amoroso,F.F.An,Q.An,Y.Bai,O.Bakina,R.Baldini Ferroli,Y.Ban,K.Begzsuren,J.V.Bennett,N.Berger,M.Bertani,D.Bettoni,F.Bianchi,J Biernat,J.Bloms,I.Boyko,R.A.Briere,L.Calibbi,H.Cai,X.Cai,A.Calcaterra,G.F.Cao,N.Cao,S.A.Cetin,J.Chai,J.F.Chang,W.L.Chang,J.Charles,G.Chelkov,Chen,G.Chen,H.S.Chen,J.C.Chen,M.L.Chen,S.J.Chen,Y.B.Chen,H.Y.Cheng,W.Cheng,G.Cibinetto,F.Cossio,X.F.Cui,H.L.Dai,J.P.Dai,X.C.Dai,A.Dbeyssi,D.Dedovich,Z.Y.Deng,A.Denig,Denysenko,M.Destefanis,S.Descotes-Genon,F.De Mori,Y.Ding,C.Dong,J.Dong,L.Y.Dong,M.Y.Dong,Z.L.Dou,S.X.Du,S.I.Eidelman,J.Z.Fan,J.Fang,S.S.Fang,Y.Fang,R.Farinelli,L.Fava,F.Feldbauer,G.Felici,C.Q.Feng,M.Fritsch,C.D.Fu,Y.Fu,Q.Gao,X.L.Gao,Y.Gao,Y.Gao,Y.G.Gao,Z.Gao,B.Garillon,I.Garzia,E.M.Gersabeck,A.Gilman,K.Goetzen,L.Gong,W.X.Gong,W.Gradl,M.Greco,L.M.Gu,M.H.Gu,Y.T.Gu,A.Q.Guo,F.K.Guo,L.B.Guo,R.P.Guo,Y.P.Guo,A.Guskov,S.Han,X.Q.Hao,F.A.Harris,K.L.He,F.H.Heinsius,T.Held,Y.K.Heng,Y.R.Hou,Z.L.Hou,H.M.Hu,J.F.Hu,T.Hu,Y.Hu,G.S.Huang,J.S.Huang,X.T.Huang,X.Z.Huang,Z.L.Huang,N.Huesken,T.Hussain,W.Ikegami Andersson,W.Imoehl,M.Irshad,Q.Ji,Q.P.Ji,X.B.Ji,X.L.Ji,H.L.Jiang,X.S.Jiang,X.Y.Jiang,J.B.Jiao,Z.Jiao,D.P.Jin,S.Jin,Y.Jin,T.Johansson,N.Kalantar-Nayestanaki,X.S.Kang,R.Kappert,M.Kavatsyuk,B.C.Ke,I.K.Keshk,T.Khan,A.Khoukaz,P.Kiese,R.Kiuchi,R.Kliemt,L.Koch,O.B.Kolcu,B.Kopf,M.Kuemmel,M.Kuessner,A.Kupsc,M.Kurth,M.G.Kurth,W.Kuhn,J.S.Lange,P.Larin,L.Lavezzi,H.Leithoff,T.Lenz,C.Li,Cheng Li,D.M.Li,F.Li,F.Y.Li,G.Li,H.B.Li,H.J.Li,J.C.Li,J.W.Li,Ke Li,L.K.Li,Lei Li,P.L.Li,P.R.Li,Q.Y.Li,W.D.Li,W.G.Li,X.H.Li,X.L.Li,X.N.Li,X.Q.Li,Z.B.Li,H.Liang,H.Liang,Y.F.Liang,Y.T.Liang,G.R.Liao,L.Z.Liao,J.Libby,C.X.Lin,D.X.Lin,Y.J.Lin,B.Liu,B.J.Liu,C.X.Liu,D.Liu,D.Y.Liu,F.H.Liu,Fang Liu,Feng Liu,H.B.Liu,H.M.Liu,Huanhuan Liu,Huihui Liu,J.B.Liu,J.Y.Liu,K.Y.Liu,Ke Liu,Q.Liu,S.B.Liu,T.Liu,X.Liu,X.Y.Liu,Y.B.Liu,Z.A.Liu,Zhiqing Liu,Y.F.Long,X.C.Lou,H.J.Lu,J.D.Lu,J.G.Lu,Y.Lu,Y.P.Lu,C.L.Luo,M.X.Luo,P.W.Luo,T.Luo,X.L.Luo,S.Lusso,X.R.Lyu,F.C.Ma,H.L.Ma,L.L.Ma,M.M.Ma,Q.M.Ma,X.N.Ma,X.X.Ma,X.Y.Ma,Y.M.Ma,F.E.Maas,M.Maggiora,S.Maldaner,S.Malde,Q.A.Malik,A.Mangoni,Y.J.Mao,Z.P.Mao,S.Marcello,Z.X.Meng,J.G.Messchendorp,G.Mezzadri,J.Min,T.J.Min,R.E.Mitchell,X.H.Mo,Y.J.Mo,C.Morales Morales,N.Yu.Muchnoi,H.Muramatsu,A.Mustafa,S.Nakhoul,Y.Nefedov,F.Nerling,I.B.Nikolaev,Z.Ning,S.Nisar,S.L.Niu,S.L.Olsen,Q.Ouyang,S.Pacetti,Y.Pan,M.Papenbrock,P.Patteri,M.Pelizaeus,H.P.Peng,K.Peters,A.A.Petrov,J.Pettersson,J.L.Ping,R.G.Ping,A.Pitka,R.Poling,V.Prasad,M.Qi,T.Y.Qi,S.Qian,C.F.Qiao,N.Qin,X.P.Qin,X.S.Qin,Z.H.Qin,J.F.Qiu,S.Q.Qu,K.H.Rashid,C.F.Redmer,M.Richter,M.Ripka,A.Rivetti,V.Rodin,M.Rolo,G.Rong,J.L.Rosner,Ch.Rosner,M.Rump,A.Sarantsev,M.Savrie,K.Schoenning,W.Shan,X.Y.Shan,M.Shao,C.P.Shen,P.X.Shen,X.Y.Shen,H.Y.Sheng,X.Shi,X.D Shi,J.J.Song,Q.Q.Song,X.Y.Song,S.Sosio,C.Sowa,S.Spataro,F.F.Sui,G.X.Sun,J.F.Sun,L.Sun,S.S.Sun,X.H.Sun,Y.J.Sun,Y.K Sun,Y.Z.Sun,Z.J.Sun,Z.T.Sun,Y.T Tan,C.J.Tang,G.Y.Tang,X.Tang,V.Thoren,B.Tsednee,I.Uman,B.Wang,B.L.Wang,C.W.Wang,D.Y.Wang,H.H.Wang,K.Wang,L.L.Wang,L.S.Wang,M.Wang,M.Z.Wang,Wang Meng,P.L.Wang,R.M.Wang,W.P.Wang,X.Wang,X.F.Wang,X.L.Wang,Y.Wang,Y.F.Wang,Z.Wang,Z.G.Wang,Z.Y.Wang,Zongyuan Wang,T.Weber,D.H.Wei,P.Weidenkaff,H.W.Wen,S.P.Wen,U.Wiedner,G.Wilkinson,M.Wolke,L.H.Wu,L.J.Wu,Z.Wu,L.Xia,Y.Xia,S.Y.Xiao,Y.J.Xiao,Z.J.Xiao,Y.G.Xie,Y.H.Xie,T.Y.Xing,X.A.Xiong,Q.L.Xiu,G.F.Xu,L.Xu,Q.J.Xu,W.Xu,X.P.Xu,F.Yan,L.Yan,W.B.Yan,W.C.Yan,Y.H.Yan,H.J.Yang,H.X.Yang,L.Yang,R.X.Yang,S.L.Yang,Y.H.Yang,Y.X.Yang,Yifan Yang,Z.Q.Yang,M.Ye,M.H.Ye,J.H.Yin,Z.Y.You,B.X.Yu,C.X.Yu,J.S.Yu,C.Z.Yuan,X.Q.Yuan,Y.Yuan,A.Yuncu,A.A.Zafar,Y.Zeng,B.X.Zhang,B.Y.Zhang,C.C.Zhang,D.H.Zhang,H.H.Zhang,H.Y.Zhang,J.Zhang,J.L.Zhang,J.Q.Zhang,J.W.Zhang,J.Y.Zhang,J.Z.Zhang,K.Zhang,L.Zhang,S.F.Zhang,T.J.Zhang,X.Y.Zhang,Y.Zhang,Y.H.Zhang,Y.T.Zhang,Yang Zhang,Yao Zhang,Yi Zhang,Yu Zhang,Z.H.Zhang,Z.P.Zhang,Z.Q.Zhang,Z.Y.Zhang,G.Zhao,J.W.Zhao,J.Y.Zhao,J.Z.Zhao,Lei Zhao,Ling Zhao,M.G.Zhao,Q.Zhao,S.J.Zhao,T.C.Zhao,Y.B.Zhao,Z.G.Zhao,A.Zhemchugov,B.Zheng,J.P.Zheng,Y.Zheng,Y.H.Zheng,B.Zhong,L.Zhou,L.P.Zhou,Q.Zhou,X.Zhou,X.K.Zhou,Xingyu Zhou,Xiaoyu Zhou,Xu Zhou,A.N.Zhu,J.Zhu,J.Zhu,K.Zhu,K.J.Zhu,S.H.Zhu,W.J.Zhu,X.L.Zhu,Y.C.Zhu,Y.S.Zhu,Z.A.Zhu,J.Zhuang,B.S.Zou,J.H.Zou,无.Future Physics Programme of BESⅢ[J].Chinese Physics C,2020,44(4). 被引量:539
  • 6严杰,李明远,孙爱华,彭宜红.2019新型冠状病毒及其感染性肺炎[J].中华微生物学和免疫学杂志,2020,40(1):1-6. 被引量:54
  • 7朱耐伟,赵平,戚中田.2019新型冠状病毒肺炎治疗研究现状[J].中华微生物学和免疫学杂志,2020,40(1):7-10. 被引量:47
  • 8李鑫,段广有,张伟,施劲松,陈嘉源,陈舜梅,高山,阮吉寿.2019新型冠状病毒S蛋白可能存在Furin蛋白酶切位点[J].生物信息学,2020,18(2):103-108. 被引量:28
  • 9Shuai Xia,Meiqin Liu,Chao Wang,Wei Xu,Qiaoshuai Lan,Siliang Feng,Feifei Qi,Linlin Bao,Lanying Du,Shuwen Liu,Chuan Qin,Fei Sun,Zhengli Shi,Yun Zhu,Shibo Jiang,Lu Lu.Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion[J].Cell Research,2020,30(4):343-355. 被引量:104
  • 10Xiaolu Tang,Changcheng Wu,Xiang Li,Yuhe Song,Xinmin Yao,Xinkai Wu,Yuange Duan,Hong Zhang,Yirong Wang,Zhaohui Qian,Jie Cui,Jian Lu.On the origin and continuing evolution of SARS-CoV-2[J].National Science Review,2020,7(6):1012-1023. 被引量:80

共引文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部